Based on reported results from 200,000+ RoenRx members
Individual results vary. Statistics shown reflect anonymized self-reported outcomes from 16,000+ U.S. RoenRx program members surveyed in May 2025; weight-loss numbers come from members’ own scale readings, waist-change figures are based on members’ tape-measure readings, and clothing-size changes reflect members’ stated apparel sizes. All results refer to participation in the full RoenRx weight loss program—which combines physician oversight, nutrition support, and, when clinically appropriate, FDA-approved GLP-1 medication or compounded GLP-1 medication dispensed by licensed pharmacies; no efficacy claims are made for any compounded drugs. Medication eligibility and outcomes depend on individual clinical evaluation. Common GLP-1 side effects include nausea and constipation; 0.3% of respondents described side effects as “unmanageable.” Consult a licensed medical professional to determine whether GLP-1 therapy within the RoenRx program is appropriate for you. The individual pictured is not an RoenRx member. Customers’ results have not been independently verified. Participants received compensation for participating in the survey.
All results refer to participation in the full Weight Loss by RoenRx program, a holistic program that combines personalized coaching, nutrition and lifestyle support, a reduced-calorie diet and exercise, and, when clinically appropriate, FDA-approved GLP-1 medication or compounded GLP-1 medication dispensed by licensed pharmacies pursuant to a prescription. Medication eligibility and outcomes depend on individual clinical evaluation. Compounded drugs provided through RoenRx have not been reviewed or approved by the U.S. Food and Drug Administration for safety or effectiveness. Before-and-after images are submitted by paid RoenRx affiliates. Results have not been independently verified and will vary from person to person. Available in all 50 states, restrictions apply. Discontinuing treatment may lead to weight regain.
Zepbound™ and Wegovy® are FDA-approved for weight loss. Ozempic® and Mounjaro® are FDA-approved for type 2 diabetes treatment, but may be prescribed off-label for weight loss at a healthcare provider’s discretion. As an alternative to FDA-approved branded products, where appropriate, a provider may prescribe a compounded drug that is effective when prescribed off label for weight loss. RoenRx-sourced compounded drugs are prepared by a state-licensed sterile compounding pharmacy, however compounded GLP-1 medications themselves are not FDA-approved.